Our Products

Depomed is committed to becoming a leader in the clinical development and commercialization of therapies for pain management and other central nervous system (CNS) conditions. The company’s current products have established Depomed’s expertise in building effective marketing strategies and solutions-oriented sales teams. The company intends to leverage this growing domain expertise with additional CNS products.

 

   

WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING
RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID | WITHDRAWAL SYNDROME; and INTERACTION WITH ALCOHOL

Addiction, Abuse, and Misuse

NUCYNTA ER exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient's risk prior to prescribing NUCYNTA ER, and monitor all patients regularly for the development of these behaviors or conditions [see Warnings and Precautions (5.1)].

Life-threatening Respiratory Depression

Serious, life-threatening, or fatal respiratory depression may occur with use of NUCYNTA ER. Monitor for respiratory depression, especially during initiation of NUCYNTA ER or following a dose increase. Instruct patients to swallow NUCYNTA ER tablets whole; crushing, chewing, or dissolving NUCYNTA ER tablets can cause rapid release and absorption of a potentially fatal dose of tapentadol [see Warnings and Precautions (5.2)].

Accidental Ingestion

Accidental ingestion of even one dose of NUCYNTA ER, especially by children, can result in a fatal overdose of tapentadol [see Warnings and Precautions (5.2)].

Neonatal Opioid Withdrawal Syndrome

Prolonged use of NUCYNTA ER during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available [see Warnings and Precautions (5.3)].

Interaction with Alcohol

Instruct patients not to consume alcoholic beverages or use prescription or nonprescription products that contain alcohol while taking NUCYNTA ER. The co-ingestion of alcohol with NUCYNTA ER may result in increased plasma tapentadol levels and a potentially fatal overdose of tapentadol [see Warnings and Precautions (5.4)].

For additional safety information and to view full Prescribing Information, please visit www.nucynta.com.

 

See full Prescribing Information and Medication Guide

For more information, please visit www.gralise.com.

 

WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS

Cardiovascular Risk

Non-steroidal anti-inflammatory drugs (NSAIDs) may increase the risk of serious cardiovascular (CV) thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk [see Warnings and Precautions (5.1)].

CAMBIA is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery [see Contraindications (4) and Warnings and Precautions (5.1)].

Gastrointestinal Risk

NSAIDs increase the risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events [see Warnings and Precautions (5.2)].

See full Prescribing Information including Boxed WARNING, and Medication Guide at www.CambiaRx.com for more information.

 

WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS

Cardiovascular Risk

Zipsor, like all nonsteroidal anti-inflammatory drugs (NSAIDs), may cause increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. (Warnings and Precautions 5.1)

Zipsor is contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery. (Contraindications 4)

Gastrointestinal Risk

NSAIDs, including Zipsor, cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach and intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events. (Warnings and Precautions 5.2)

See full prescribing information for complete boxed warning.

See full Prescribing Information including Boxed WARNING regarding cardiovascular and gastrointestinal risks

For more information, please visit www.zipsor.com.

 

If you have any questions regarding our marketed products, please call 1.866.458.6389.

Improving Patient Lives

IIn addition to its core CNS and pain therapeutics, NUCYNTA ER, NUCYNTA, Gralise, Cambia, and Zipsor, Depomed is enhancing therapeutic outcomes through the incorporation of its Acuform® drug delivery technology in products marketed by the company’s strategic partners. Acuform is a proprietary gastroretentive polymer formulation that allows continuous, controlled delivery of drug compounds with one or two oral doses. Products based on Acuform may provide patients and caregivers with greater convenience, more efficient absorption, enhanced safety and increased efficacy.